0557.Hk
The company operates in the healthcare sector, specifically in the provision of healthcare facilities and services, and is engaged in the pharmaceuticals activity.
Business. The company operates in the healthcare sector, specifically in the provision of healthcare facilities and services, and is engaged in the pharmaceuticals activity.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, specifically in the provision of healthcare facilities and services, and is engaged in the pharmaceuticals activity.
The company's capital structure is characterized by a debt-to-equity ratio of 0.24, indicating a relatively low level of leverage compared to the industry median. The liquidity position is marked by cash and equivalents of 27,733,000 HKD, which is partially offset by long-term debt of 38,716,000 HKD, resulting in a net cash position that is negative. The market capitalization of 183,530,581.04 HKD suggests a modest valuation relative to its revenue of 19,178,000 HKD, with an enterprise value to revenue ratio of 10.14.
Profitability metrics are not explicitly provided, but the company's revenue of 19,178,000 HKD and the industry's preferred metrics suggest a need for further analysis to determine its performance relative to the cohort median. The company's earnings per share of 0.13 HKD and the reported revenue of 65,270,000 HKD for the last actual period indicate a potential for growth.
The company's segments and geographic exposure are not detailed in the provided data, but the revenue concentration and the nature of the business suggest that it may be focused on a specific market or region. The lack of detailed segment information limits the ability to assess the diversification of its revenue streams.
The growth trajectory of the company is not explicitly outlined, but the current financial performance and the industry outlook suggest that the company may be in a phase of moderate growth. The revenue history and the analyst estimates indicate a stable performance, with the potential for future expansion.
The risk assessment of the company highlights a medium liquidity risk and a low dilution risk. The key flag of a negative net cash position after subtracting total debt suggests that the company may need to manage its liquidity carefully. The dilution potential is low, and no adjustments have been applied to the valuation metrics.
Recent events and filings have not been detailed in the provided data, but the company's financial snapshot and valuation metrics suggest that it has maintained a stable financial position. The absence of recent events does not necessarily indicate a lack of activity, but rather a lack of disclosed information.
- The company has a relatively low debt-to-equity ratio, indicating a conservative capital structure.
- The enterprise value to revenue ratio of 10.14 suggests a modest valuation relative to its revenue.
- The company's liquidity position is marked by a negative net cash position after subtracting total debt.
- The company's earnings per share and revenue figures indicate a stable financial performance.
- The risk assessment indicates a medium liquidity risk and a low dilution risk.
- The company's growth trajectory is not explicitly outlined, but the financial performance suggests a potential for moderate growth.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Enterprise Valuemarket_cap - net_cash
- 0557.HK Market data — financials · 2026-05-26
- China Tian Yuan Healthcare Group Ltd Market data — analyst estimates · 2026-05-26